TY - JOUR
T1 - FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma
AU - Walker, Matthew P.
AU - Stopford, Charles M.
AU - Cederlund, Maria
AU - Fang, Fang
AU - Jahn, Christopher
AU - Rabinowitz, Alex D.
AU - Goldfarb, Dennis
AU - Graham, David M.
AU - Yan, Feng
AU - Deal, Allison M.
AU - Fedoriw, Yuri
AU - Richards, Kristy L.
AU - Davis, Ian J.
AU - Weidinger, Gilbert
AU - Damania, Blossom
AU - Major, Michael B.
PY - 2015/2/3
Y1 - 2015/2/3
N2 - The transcription factor FOXP1 (forkhead box protein P1) is a master regulator of stem and progenitor cell biology. In diffuse large B cell lymphoma (DLBCL), copy number amplifications and chromosomal translocations result in overexpression ofFOXP1. Increased abundance ofFOXP1 in DLBCL is a predictor of poor prognosis and resistance to therapy.Wedeveloped a genome-wide, mass spectrometry-coupled, gain-of-function genetic screen,which revealed that FOXP1 potentiates β-catenin-dependent,Wnt-dependent gene expression. Gain-and loss-of-function studies in cell models and zebrafish confirmed that FOXP1 was a general and conserved enhancer of Wnt signaling. In a Wnt-dependent fashion, FOXP1 formed a complex with β-catenin, TCF7L2 (transcription factor 7-like 2), and the acetyltransferase CBP [CREB (adenosine 3′,5′-monophosphate response element-binding protein)-binding protein], and this complex bound the promoters of Wnt target genes. FOXP1 promoted the acetylation of β-catenin by CBP, and acetylation was required for FOXP1-mediated potentiation of β-catenin-dependent transcription. In DLBCL, we found that FOXP1 promoted sensitivity to Wnt pathway inhibitors, and knockdown of FOXP1 or blocking β-catenin transcriptional activity slowed xenograft tumor growth. These data connect excessive FOXP1 with β-catenin-dependent signal transduction and provide a molecular rationale for Wnt-directed therapy in DLBCL.
AB - The transcription factor FOXP1 (forkhead box protein P1) is a master regulator of stem and progenitor cell biology. In diffuse large B cell lymphoma (DLBCL), copy number amplifications and chromosomal translocations result in overexpression ofFOXP1. Increased abundance ofFOXP1 in DLBCL is a predictor of poor prognosis and resistance to therapy.Wedeveloped a genome-wide, mass spectrometry-coupled, gain-of-function genetic screen,which revealed that FOXP1 potentiates β-catenin-dependent,Wnt-dependent gene expression. Gain-and loss-of-function studies in cell models and zebrafish confirmed that FOXP1 was a general and conserved enhancer of Wnt signaling. In a Wnt-dependent fashion, FOXP1 formed a complex with β-catenin, TCF7L2 (transcription factor 7-like 2), and the acetyltransferase CBP [CREB (adenosine 3′,5′-monophosphate response element-binding protein)-binding protein], and this complex bound the promoters of Wnt target genes. FOXP1 promoted the acetylation of β-catenin by CBP, and acetylation was required for FOXP1-mediated potentiation of β-catenin-dependent transcription. In DLBCL, we found that FOXP1 promoted sensitivity to Wnt pathway inhibitors, and knockdown of FOXP1 or blocking β-catenin transcriptional activity slowed xenograft tumor growth. These data connect excessive FOXP1 with β-catenin-dependent signal transduction and provide a molecular rationale for Wnt-directed therapy in DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=84922458222&partnerID=8YFLogxK
U2 - 10.1126/scisignal.2005654
DO - 10.1126/scisignal.2005654
M3 - Article
C2 - 25650440
AN - SCOPUS:84922458222
SN - 1945-0877
VL - 8
JO - Science signaling
JF - Science signaling
IS - 362
M1 - ra12
ER -